Skip to main content
Erschienen in:

11.07.2017 | original article

Intracameral moxifloxacin for prophylaxis of postoperative endophthalmitis

verfasst von: Nedime Sahinoglu-Keskek, MD, Prof. Aysel Pelit

Erschienen in: Spektrum der Augenheilkunde | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Summary

Background

The aim of this study was to evaluate the rates of post-cataract-surgery endophthalmitis after prophylactic intracameral moxifloxacin administration.

Methods

In this retrospective descriptive study, 1013 uncomplicated cataract surgeries with intraocular lens implantation were performed between March 2009 and November 2013 by one surgeon (AP). Each patient received an intracameral injection of 0.05 ml undiluted 0.5% moxifloxacin for prophylaxis of postoperative infection.

Results

The mean follow-up of patients was 1 year (range: 2 months to 4 years), and the mean age of the patients was 64.2 years (range: 38–99 years). Of the 1013 patients, 617 (58.6%) were women. No case of endophthalmitis occurred.

Conclusion

No postoperative endophthalmitis was observed after the intracameral injection of 0.5% moxifloxacin ophthalmic solution during routine cataract surgery.
Literatur
1.
Zurück zum Zitat Barry P, Seal DV, Gettinby G, et al. ESCRS study of prophylaxis of postoperative endophthalmitis after cataract surgery: preliminary report of principal results from a Europeanmulticenter study. J Cataract Refract Surg. 2006;32:407–10.CrossRefPubMed Barry P, Seal DV, Gettinby G, et al. ESCRS study of prophylaxis of postoperative endophthalmitis after cataract surgery: preliminary report of principal results from a Europeanmulticenter study. J Cataract Refract Surg. 2006;32:407–10.CrossRefPubMed
2.
Zurück zum Zitat Endophthalmitis Study Group. European Society of Cataract & Refractive Surgeons. Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors. J Cataract Refract Surg. 2007;33:978–88.CrossRef Endophthalmitis Study Group. European Society of Cataract & Refractive Surgeons. Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors. J Cataract Refract Surg. 2007;33:978–88.CrossRef
3.
Zurück zum Zitat Frilling E, Lundström M, Stenevi U, Montan P. Six-year incidence of endophthalmitis after cataract surgery: Swedish national study. J Cataract Refract Surg. 2013;39:15–21.CrossRef Frilling E, Lundström M, Stenevi U, Montan P. Six-year incidence of endophthalmitis after cataract surgery: Swedish national study. J Cataract Refract Surg. 2013;39:15–21.CrossRef
4.
Zurück zum Zitat Espiritu CRG, Caparas VL, Bolinao JG. Safety of prophylactic intracameral moxifloxacin 0.5 % ophthalmic solution in cataract surgery patients. J Cataract Refract Surg. 2007;33:63–8.CrossRefPubMed Espiritu CRG, Caparas VL, Bolinao JG. Safety of prophylactic intracameral moxifloxacin 0.5 % ophthalmic solution in cataract surgery patients. J Cataract Refract Surg. 2007;33:63–8.CrossRefPubMed
5.
Zurück zum Zitat Kim SY, Park Y‑H, Lee Y‑C. Comparison of the effect of intracameral moxifloxacin, levofloxacin and cefazolin on rabbit corneal endothelial cells. Clin Experiment Ophthalmol. 2008;36:367–70.CrossRefPubMed Kim SY, Park Y‑H, Lee Y‑C. Comparison of the effect of intracameral moxifloxacin, levofloxacin and cefazolin on rabbit corneal endothelial cells. Clin Experiment Ophthalmol. 2008;36:367–70.CrossRefPubMed
6.
Zurück zum Zitat Lane SS, Osher RH, Masket S, Belani S. Evaluation of the safety of prophylactic intracameral moxifloxacin in cataract surgery. J Cataract Refract Surg. 2008;34:1451–9.CrossRefPubMed Lane SS, Osher RH, Masket S, Belani S. Evaluation of the safety of prophylactic intracameral moxifloxacin in cataract surgery. J Cataract Refract Surg. 2008;34:1451–9.CrossRefPubMed
7.
Zurück zum Zitat O’Brien TP, Arshinoff SA, Mah FS. Perspectives on antibiotics for postoperative endophthalmitis prophylaxis: potential role of moxifloxacin. J Cataract Refract Surg. 2007;33:1790–800.CrossRefPubMed O’Brien TP, Arshinoff SA, Mah FS. Perspectives on antibiotics for postoperative endophthalmitis prophylaxis: potential role of moxifloxacin. J Cataract Refract Surg. 2007;33:1790–800.CrossRefPubMed
8.
Zurück zum Zitat Arbisser LB. Safety of intracameral moxifloxacin for prophylaxis of endophthalmitis after cataract surgery. J Cataract Refract Surg. 2008;34:1114–20.CrossRefPubMed Arbisser LB. Safety of intracameral moxifloxacin for prophylaxis of endophthalmitis after cataract surgery. J Cataract Refract Surg. 2008;34:1114–20.CrossRefPubMed
9.
Zurück zum Zitat Matsuura K, Suto C, Akura J, Inoue Y. Bag and chamber flushing: a new method of using intracameral moxifloxacin to irrigate the anterior chamber and the area behind the intraocular lens. Graefes Arch Clin Exp Ophthalmol. 2013;251:81–7.CrossRefPubMed Matsuura K, Suto C, Akura J, Inoue Y. Bag and chamber flushing: a new method of using intracameral moxifloxacin to irrigate the anterior chamber and the area behind the intraocular lens. Graefes Arch Clin Exp Ophthalmol. 2013;251:81–7.CrossRefPubMed
10.
Zurück zum Zitat Kowalski RP, Romanowski EG, Mah FS, et al. Intracameral Vigamox (moxifloxacin 0.5 %) is non-toxic and effective in preventing endophthalmitis in a rabbit model. Am J Ophthalmol. 2005;140:497–504.CrossRefPubMed Kowalski RP, Romanowski EG, Mah FS, et al. Intracameral Vigamox (moxifloxacin 0.5 %) is non-toxic and effective in preventing endophthalmitis in a rabbit model. Am J Ophthalmol. 2005;140:497–504.CrossRefPubMed
11.
Zurück zum Zitat Stroman DW, Dajcs JJ, Cupp GA, Schlech BA. In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5 %; a new topical fluoroquinolone. Surv Ophthalmol. 2005;50:16–31.CrossRef Stroman DW, Dajcs JJ, Cupp GA, Schlech BA. In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5 %; a new topical fluoroquinolone. Surv Ophthalmol. 2005;50:16–31.CrossRef
12.
Zurück zum Zitat West ES, Behrens A, McDonnell PJ, et al. The incidence of endophthalmitis after cataract surgery among the U.S. Medicare population between 1994 and 2001. Ophthalmology. 2005;112:1388–94.CrossRefPubMed West ES, Behrens A, McDonnell PJ, et al. The incidence of endophthalmitis after cataract surgery among the U.S. Medicare population between 1994 and 2001. Ophthalmology. 2005;112:1388–94.CrossRefPubMed
13.
Zurück zum Zitat Ciulla TA, Starr MB, Masket S. Bacterial endophthalmitis prophylaxis for cataract surgery; an evidence-based update. Ophthalmology. 2002;109:13–24, questions for CME credit request, 25–26.CrossRefPubMed Ciulla TA, Starr MB, Masket S. Bacterial endophthalmitis prophylaxis for cataract surgery; an evidence-based update. Ophthalmology. 2002;109:13–24, questions for CME credit request, 25–26.CrossRefPubMed
14.
Zurück zum Zitat Isenberg SJ, Apt L, Yoshimori R, et al. Efficacy of topical povidoneiodine during the first week after ophthalmic surgery. Am J Ophthalmol. 1997;124:31–5.CrossRefPubMed Isenberg SJ, Apt L, Yoshimori R, et al. Efficacy of topical povidoneiodine during the first week after ophthalmic surgery. Am J Ophthalmol. 1997;124:31–5.CrossRefPubMed
15.
Zurück zum Zitat Arshinoff SA, Bastianelli PA. Incidence of postoperative endophthalmitis after immediate sequential bilateral cataract surgery. J Cataract Refract Surg. 2011;37:2105–14.CrossRefPubMed Arshinoff SA, Bastianelli PA. Incidence of postoperative endophthalmitis after immediate sequential bilateral cataract surgery. J Cataract Refract Surg. 2011;37:2105–14.CrossRefPubMed
16.
Zurück zum Zitat Lin M, Zhang W, Liu Y, et al. Nosocomial acute-onset postoperative endophthalmitis at a university teaching hospital in China. J Hosp Infect. 2011;79:323–7.CrossRefPubMed Lin M, Zhang W, Liu Y, et al. Nosocomial acute-onset postoperative endophthalmitis at a university teaching hospital in China. J Hosp Infect. 2011;79:323–7.CrossRefPubMed
17.
Zurück zum Zitat Ozlem TY, Necati DM, Fatma YM, et al. Are cefuroxime and vancomycin really safe on the corneal endothelial cells? Graefes Arch Clin Exp Ophthalmol. 2010;248(3):415–20.CrossRefPubMed Ozlem TY, Necati DM, Fatma YM, et al. Are cefuroxime and vancomycin really safe on the corneal endothelial cells? Graefes Arch Clin Exp Ophthalmol. 2010;248(3):415–20.CrossRefPubMed
18.
Zurück zum Zitat Delyfer MN, Rougier MB, Leoni S, et al. Ocular toxicity after intracameral injection of very high doses of cefuroxime during cataract surgery. J Cataract Refract Surg. 2011;37(2):271–8.CrossRefPubMed Delyfer MN, Rougier MB, Leoni S, et al. Ocular toxicity after intracameral injection of very high doses of cefuroxime during cataract surgery. J Cataract Refract Surg. 2011;37(2):271–8.CrossRefPubMed
19.
Zurück zum Zitat Alfonso E, Crider J. Ophthalmic infections and their anti-infective challenges. Surv Ophthalmol. 2005;50:1–6.CrossRef Alfonso E, Crider J. Ophthalmic infections and their anti-infective challenges. Surv Ophthalmol. 2005;50:1–6.CrossRef
20.
Zurück zum Zitat Schlech BA, Alfonso E. Overview of the potency of moxifloxacin ophthalmic solution 0.5 % (Vigamox). Surv Ophthalmol. 2005;50:7–15.CrossRef Schlech BA, Alfonso E. Overview of the potency of moxifloxacin ophthalmic solution 0.5 % (Vigamox). Surv Ophthalmol. 2005;50:7–15.CrossRef
21.
Zurück zum Zitat Trinkhaus-Randall V, Edelhauser HF, Leibowitz HM, Freddo TF. Corneal structure and function. In: Leibowitz HM, Waring GO III, editors. Corneal disorders; clinical diagnosis and management, 2nd edn. Philadelphia PA: WB Saunders; 1998. pp. 21–7. Trinkhaus-Randall V, Edelhauser HF, Leibowitz HM, Freddo TF. Corneal structure and function. In: Leibowitz HM, Waring GO III, editors. Corneal disorders; clinical diagnosis and management, 2nd edn. Philadelphia PA: WB Saunders; 1998. pp. 21–7.
22.
Zurück zum Zitat Shorstein NH, Winthrop KL, Herrinton LJ. Decreased postoperative endophthalmitis rate after institution of intracameral antibiotics in a Northern California eye department. J Cataract Refract Surg. 2013;39(1):8–14.CrossRefPubMed Shorstein NH, Winthrop KL, Herrinton LJ. Decreased postoperative endophthalmitis rate after institution of intracameral antibiotics in a Northern California eye department. J Cataract Refract Surg. 2013;39(1):8–14.CrossRefPubMed
23.
Zurück zum Zitat Galvis V, Tello A, Sánchez MA, Camacho PA. Cohort study of intracameral moxifloxacin in postoperative endophthalmitis prophylaxis. Ophthalmol Eye Dis. 2014;6:1–4.PubMedPubMedCentral Galvis V, Tello A, Sánchez MA, Camacho PA. Cohort study of intracameral moxifloxacin in postoperative endophthalmitis prophylaxis. Ophthalmol Eye Dis. 2014;6:1–4.PubMedPubMedCentral
24.
Zurück zum Zitat Haripriya A, Chang DF, Namburar S, Smita A, Ravindran RD. Efficacy of Intracameral moxifloxacin endophthalmitis prophylaxis at aravind eye hospital. Ophthalmology. 2016;123(2):302–8.CrossRefPubMed Haripriya A, Chang DF, Namburar S, Smita A, Ravindran RD. Efficacy of Intracameral moxifloxacin endophthalmitis prophylaxis at aravind eye hospital. Ophthalmology. 2016;123(2):302–8.CrossRefPubMed
25.
Zurück zum Zitat Haripriya A, Chang DF, Ravindran RD. Endophthalmitis reduction with intracameral moxifloxacin prophylaxis: analysis of 600 000 surgeries. Ophthalmology. 2017;124(6):768–75.CrossRefPubMed Haripriya A, Chang DF, Ravindran RD. Endophthalmitis reduction with intracameral moxifloxacin prophylaxis: analysis of 600 000 surgeries. Ophthalmology. 2017;124(6):768–75.CrossRefPubMed
26.
Zurück zum Zitat Zhou AX, Messenger WB, Sargent S, Ambati BK. Safety of undiluted intracameral moxifloxacin without postoperative topical antibiotics in cataract surgery. Int Ophthalmol. 2016;36(4):493–8.CrossRefPubMed Zhou AX, Messenger WB, Sargent S, Ambati BK. Safety of undiluted intracameral moxifloxacin without postoperative topical antibiotics in cataract surgery. Int Ophthalmol. 2016;36(4):493–8.CrossRefPubMed
Metadaten
Titel
Intracameral moxifloxacin for prophylaxis of postoperative endophthalmitis
verfasst von
Nedime Sahinoglu-Keskek, MD
Prof. Aysel Pelit
Publikationsdatum
11.07.2017
Verlag
Springer Vienna
Erschienen in
Spektrum der Augenheilkunde / Ausgabe 5/2017
Print ISSN: 0930-4282
Elektronische ISSN: 1613-7523
DOI
https://doi.org/10.1007/s00717-017-0350-0

Weitere Artikel der Ausgabe 5/2017

Spektrum der Augenheilkunde 5/2017 Zur Ausgabe